Citigroup
IMRX icon

Citigroup’s Immuneering IMRX Stock Holding History

Citigroup’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Sell
26,313
-14,104
-35% -$71.3K ﹤0.01% 4535
2026
Q1 		$213K Buy
40,417
+2,880
+8% +$14.8K ﹤0.01% 3979
2025
Q4 		$247K Buy
37,537
+36,741
+4,616% +$236K ﹤0.01% 3898
2025
Q3 		$5.57K Hold
796
– – ﹤0.01% 5205
2025
Q2 		$2.68K Hold
796
– – ﹤0.01% 5339
2025
Q1 		$1.21K Sell
796
-1,501
-65% -$2.73K ﹤0.01% 5365
2024
Q4 		$5.05K Buy
2,297
+1,501
+189% +$3.11K ﹤0.01% 5460
2024
Q3 		$1.98K Sell
796
-3,891
-83% -$5.66K ﹤0.01% 5415
2024
Q2 		$6K Sell
4,687
-801
-15% -$1.32K ﹤0.01% 5232
2024
Q1 		$15.9K Buy
5,488
+1,721
+46% +$9.64K ﹤0.01% 5101
2023
Q4 		$27.7K Buy
3,767
+3,078
+447% +$20.5K ﹤0.01% 4848
2023
Q3 		$5.29K Sell
689
-5,847
-89% -$53.8K ﹤0.01% 4706
2023
Q2 		$66.3K Buy
6,536
+6,236
+2,079% +$60K ﹤0.01% 4475
2023
Q1 		$2.91K Sell
300
-103
-26% -$585 ﹤0.01% 5045
2022
Q4 		$1.96K Sell
403
-3,806
-90% -$33.7K ﹤0.01% 5246
2022
Q3 		$60K Buy
4,209
+3,280
+353% +$26K ﹤0.01% 4307
2022
Q2 		$6K Sell
929
-599
-39% -$3.19K ﹤0.01% 5549
2022
Q1 		$9K Sell
1,528
-1,430
-48% -$13.7K ﹤0.01% 5576
2021
Q4 		$48K Buy
2,958
+1,712
+137% +$41.7K ﹤0.01% 5083
2021
Q3 		$33K Buy
+1,246
New +$33.5K ﹤0.01% 4980

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citigroup's IMRX Position: Q2 2026 in Review

Citigroup reduced its Immuneering (IMRX) stake by 35% in Q2 2026, selling an estimated $71.3K and leaving 26,313 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #4535.

Citigroup first reported a position in IMRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $247K in Q4 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Citigroup held 26,313 shares of Immuneering worth $131K as of Q2 2026.
  • Citigroup sold 14,104 Immuneering shares in Q2 2026, an estimated $71.3K.
  • Immuneering made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4535 holding.
  • Citigroup first reported a position in Immuneering in Q3 2021 and has held it in 20 quarters since.
  • Citigroup's Immuneering position peaked at $247K in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.